A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer

NCT Number	NCT04351555
Lead Sponsor	AstraZeneca
Conditions	Non-Small Cell Lung Cancer
Enrollment	358 participants
Start Date	2020-12-16
Primary Completion	2024-10-15 (estimated)
Study Completion	2029-06-13 (estimated)
Updated on ClinicalTrials.gov	2026-06-05